« Previous Next » Epilepsy Research
Volume 26, Issue 2 , Pages 381-388 , January 1997

Mutual interaction between remacemide hydrochloride and phenytoin

Received 10 July 1996 ,Revised 23 September 1996 ,Accepted 26 September 1996.

References

Bannan, P.E., Graham, D.I., Lees, K.R. and McCulloch J., Neuroprotective effect of remacemide hydrochloride in focal cerebral ischaemia in the cat, Brain Res., 664 (1994) 271–275.
Brodie. M.J. and Dichter, M.A., Antiepileptic drugs, N. Engl. J. Med., 334 (1996) 168–175.
Brodie, M.J., Drug interactions and epilepsy, Epilepsia, 33 (1992) Suppl. 1, S13–S22.
Clark, B., Hutchison, J.B., Jamieson, V., Jones, T., Palmer, G.C. and Scheyer, R.D., Potential antiepileptic drugs: remacemide hydrochloride. In: R.H. Levy, R.H. Mattson and B.S. Meldrum (Eds.), Antiepileptic Drugs (4th edition), Raven Press, New York, 1995, pp. 1035–1044.
Flynn, J.W. and O'Brien, J., High performance liquid chromatographic method for the simultaneous measurement of remacemide (a novel anticonvulsant and cerebroprotectant) and an active metabolite in human plasma, J. Chromatogr., 583 (1992) 91–97.
Garske, G.E., Palmer, G.C., Napier J.J., Griffith, R.C., Freedman, L.R., Harris, E.W., Ray, R., McCreedy, S.A., Blosser, J.C., Woodhead, J.H., White, H.S. and Swinyard, E.A., Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat, Epilepsy Res., 9 (1991) 161–174.
Greenamyre, J.T., Eller, R.V., Zhang, Z., Ovadia, A., Kurlan, R. and Gash, D.M., Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease, Ann. Neurol., 35 (1994) 655–661.
Heyn, H., McCarthy, D.J., Curry, S.H., Eisman, M.S. and Anders, M.W., Brain uptake and biotransformation of remacemide hydrochloride, a novel anticonvulsant, Drug Metab. Dispos., 22 (1994) 443–446.
Leach, J.P., Blacklaw, J., Jamieson, V., Jones, T., Richens, A. and Brodie, M.J., Mutual interactions between remacemide hydrochloride and carbamazepine two drugs with active metabolites, Epilepsia, 37 (1996) 1100–1106.
Levy, R.H., Cytochrome P450 isoenzymes and antiepileptic drug interactions, Epilepsia, 36 (1995) Suppl. 5, S8–S13.
McKee, P.J.W., Blacklaw, J., Forrest, G., Gillham, R., Walker, S., Connelly, D. and Brodie, M.J., A double-blind, placebo controlled interaction study between oxcarbazepine, carbamazepine, sodium valproate and phenytoin in epileptic patients, Br. J. Clin. Pharmacol., 37 (1994) 27–32.
McKee, P.J.W. and Brodie, M.J., Pharmacokinetic interactions with antiepileptic drugs. In: M.R. Trimble (Ed.), New Anticonvulsants: Advances in the Treatment of Epilepsy, Wiley, Chichester, 1994, pp. 1–33.
Muir, K.T. and Palmer, G.C., Remacemide. In: F. Pisani, E. Perucca, G. Avanzini, A. Richens (Eds.), New Antiepileptic Drugs. Epilepsy Res., (1991) Suppl. 3, 147–156.
Palmer, G.C., Harris, E.W., Ray, R., Stagnitto, M.L. and Schmiesing, R.J., Classification of compounds for prevention of NMDA-induced seizures/mortality, or maximal electroshock and pentylenetetrazol seizures in mice and antagonism of MK801 binding in vitro, Arch. Int. Pharmacodyn. Ther., 317 (1992) 16–34.
Palmer, G.C., Murray, R.J., Wilson, T.C. et al., Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide, Epilepsy Res., 12 (1992) 9–20.
Wilson, J.F., Tsanaclis, L.M., Perret, J.E., Williams, J., Wicks, J.F.C. and Richens, A., Performance of techniques for measurement of therapeutic drugs in serum. A comparison based on external quality assessment data, Ther. Drug Monit., 14 (1992) 98–106.